<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424970</url>
  </required_header>
  <id_info>
    <org_study_id>APCA06</org_study_id>
    <secondary_id>Legs Poix 999</secondary_id>
    <nct_id>NCT00424970</nct_id>
  </id_info>
  <brief_title>Treatment of High Altitude Polycythemia by Acetazolamide</brief_title>
  <official_title>Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour la Recherche en Physiologie de l'Environnement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Paris 13</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Legs Poix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association pour la Recherche en Physiologie de l'Environnement</source>
  <brief_summary>
    <textblock>
      The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and
      15% in the high altitude regions of South America. There is no pharmacological treatment
      available. After a first preliminary study in 2003 demonstrating the beneficial effects of
      acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want
      to confirm this effect and implement a treatment protocol of 3 month-duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic mountain sickness (CMS) is characterized by an excessive number of red cells in the
      blood of persons living permanently above the altitude of 2,500m. The symptoms of this very
      incapacitating disease are : headaches, chronic asthenia, digestive troubles, sleep
      disturbances. The hemoglobin concentration is higher than 21 g/dl of blood. In addition,
      patients show a pulmonary hypertension of variable degree, as well as a systemic
      hypertension.

      This disease affects essentially males, but women are also concerned after menopause. The
      evolution of the disease is always very dramatic, towards a cardiac failure and cerebral
      vascular stroke. The prevalence is between 8% and 15% on the Andean Altiplano . No
      pharmacological treatment is available.

      A preliminary study was performed (Richalet et al. AJRCCM, 2005) that demonstrated the
      efficiency of acetazolamide (a carbonic anhydrase inhibitor) in reducing the hematocrit and
      the erythropoetin concentration,and increasing nocturnal oxygen saturation in patients
      suffering from CMS, after 3 weeks of treatment.

      We plan to perform a double-blinded placebo-controlled study to evaluate the efficiency of a
      3-month treatment with daily 250 mg acetazolamide to reduce the hematocrit and hemoglobin
      concentrations and ameliorate the clinical symptoms of 55 patients suffering from CMS and
      living at high altitude (Cerro de Pasco, Peru).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic pulmonary arterial pressure</measure>
    <time_frame>before and after 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vascular resistance</measure>
    <time_frame>before and after 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen saturation at rest</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical score of Chronic Mountain Sickness</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of lofe score</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>High Altitude Polycythemia</condition>
  <arm_group>
    <arm_group_label>acetazolamide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>acetazolamide 250mg /day oral administration, for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetazolamide</intervention_name>
    <arm_group_label>acetazolamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Chronic mountain sickness and Hb &gt; 21g/dl

        Exclusion Criteria:

          -  patients smokers

          -  patients with respiratory or cardiovascular or renal disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Richalet, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARPE, University Paris 13</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabiola Leon-Velarde, PHD</last_name>
    <role>Study Director</role>
    <affiliation>University Cayetano Heredia, Lima, Peru</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>100</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <reference>
    <citation>Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, Bienvenu A, Lasne F, Moutereau S, Le√≥n-Velarde F. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1427-33. Epub 2005 Aug 26.</citation>
    <PMID>16126936</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <keyword>high altitude</keyword>
  <keyword>hypoxia</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>polycythemia</keyword>
  <keyword>hypoventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

